Category: St. Jude Medical
A federal appeals court partially overturns a lower court's ruling in favor of St. Jude Medical in a lawsuit against Access Closure over vascular closure patents.
The FDA's Circulatory System Devices Panel will in October reconsider CardioMEMs' once-rejected application for its Champion heart failure monitoring system, a potential boon for stakeholder St. Jude Medical.
Once-rejected CardioMEMs will get another shot at FDA approval for its Champion implantable heart failure monitoring systems when the agency's Circulatory System Devices Panel convenes next month, according to a notice in the Federal Register.
California-based Spinal Modulation enrolls the 1st patient in its ACCURATE clinical trial to evaluate its Axium neurostimulation system for management of chronic lower limb pain, a technology that St. Jude Medical has under an exclusive acquisition option.
St. Jude Medical wins CE Mark approval in the European Union for its next-generation EnligHTN renal denervation system, which can purportedly ablation time by as much as 80%.
St. Jude Medical acquires Endosense and its TactiCath force-sensing ablation catheter in a deal worth up to $331 million.
The FDA gives St. Jude the stamp of approval for its new ablation catheters, souped-up with GPS-like navigations system that help doctors visualize a catheter in the body.
With FDA approval in hand, St. Jude Medical (NYSE:STJ) launched a new and improved ablation catheter that features a GPS-like body navigation system called MediGuide.
A Minnesota federal judge rules for W.L. Gore in its patent spat with St. Jude Medical acquisition AGA Medical over heart implants.
W.L. Gore & Assoc. claimed a win in its patent war with St. Jude Medical (NYSE:STJ) over heart defect repair technology, after a federal judge in Minnesota dismissed the suit.